


# Serum IL-35 levels tied to bone loss with rheumatoid arthritis

September 27 2019

---



Serum interleukin (IL)-35 levels are associated with bone loss and may

represent a novel therapeutic target for postmenopausal women with rheumatoid arthritis (RA), according to a study published online Aug. 26 in *Mediators of Inflammation*.

Yuxuan Li, from the First Affiliated Hospital of China Medical University in Shenyang, and colleagues explored the correlations between IL-35 levels and bone loss in postmenopausal women, including 76 with RA and 53 healthy controls. Additionally, dual-energy X-ray absorptiometry was used to measure bone mineral density (BMD) at lumbar spine 1 to 4 and at total hip.

The researchers found that serum IL-35 levels were increased in RA patients compared with healthy controls. Additionally, serum IL-35 level positively correlated with BMD and 25-hydroxyvitamin D3 level and negatively correlated with  $\beta$ -isomerised carboxy-terminal cross-linking telopeptide of type I collagen in postmenopausal women with RA. Women with higher alkaline phosphatase (ALP) levels had higher serum IL-35 levels than those in the normal ALP group.

"IL-35, an important anti-inflammatory cytokine, may participate in the pathogenesis of [bone loss](#) in [postmenopausal women](#) with RA," the authors write.

**More information:** [Abstract/Full Text](#)

Copyright © 2019 [HealthDay](#). All rights reserved.

Citation: Serum IL-35 levels tied to bone loss with rheumatoid arthritis (2019, September 27) retrieved 27 April 2024 from <https://medicalxpress.com/news/2019-09-serum-il-tied-bone-loss.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private

study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.